Erythropoietin and long-acting erythropoiesis stimulating agent ameliorate non-alcoholic fatty liver disease by increasing lipolysis and decreasing lipogenesis via EPOR/STAT pathway
Tsuma, Yusuke, Mori, Jun, Ota, Takeshi, Kawabe, Yasuhiro, Morimoto, Hidechika, Fukuhara, Shota, Kodo, Kazuki, Umemura, Atsushi, Nakajima, Hisakazu, Hosoi, HajimeТом:
509
Мова:
english
Журнал:
Biochemical and Biophysical Research Communications
DOI:
10.1016/j.bbrc.2018.12.131
Date:
January, 2019
Файл:
PDF, 2.48 MB
english, 2019
File converter
Більше результатів пошуку
More benefits 
